FGFR1 and cancer: These alterations include RB1 loss, APC loss, MYC amplification, and AKT2 amplification, as well as alterations involving genes with high cancer patient population frequencies in the METABRIC dataset [57], i.e., FGFR1 amplification (14% patient population frequency) and AURKA amplification (6% patient population frequency).